In children with new onset T1D, low-dose, twice daily oral GABA, with/or without GAD-alum antigen stimulation, inhibited glucagon and reduced Th1 inflammatory cytokine release. This evidence concerns the gene GAD1 and type 1 diabetes mellitus.